An Irish medtech company, Innovation Zed, today announced that it has commenced working with the NHS in South Yorkshire and Bassetlaw, England.
This collaboration will involve the use of the company’s novel insulin pen accessory on diabetes patients, as part of a national NHS Test Bed programme.
The South Yorkshire and Bassetlaw Perfect Patient Pathway Test Bed is one of seven NHS-funded national programmes in England exploring new ways of delivering care to patients by working with technology partners.
The snap-on accessory, entitled InsulCheck Connect, is for the use of disposable insulin pen users, automatically collecting and recording pen usage and behaviour data ‘on the go’.
The InsulCheck Connect will collect data that will be used alongside other information, such as sugar level readings, to enable diabetic patients and their medical professionals to improve the management of the condition and generate better health outcomes. The diabetes device will be offered to up to 300 diabetic patients at the Northern General Hospital, Sheffield.
Once the Test Bed programme results have been evaluated, any models and technology that is seen as successfully supporting patients to improve their care could be made available to other parts of the UK, to adopt and adapt depending on the particular needs of their local populations.
Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD), was co-founded in 2009 by John Hughes and William Cirillo.
John Hughes, CEO of Innovation Zed and also an insulin user commented: “Our research with insulin pen users highlights that, as with other conditions, injection compliance is significantly below what is prescribed.
“We firmly believe that this work will demonstrate that our insulin pen accessory can greatly improve injection compliance and generate better health outcomes for people with diabetes”.